Study guide
18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
Key Takeaways Explain This Topic AI
The IHI Model for Improvement pairs three questions (aim, measures, changes) with small, rapid Plan-Do-Study-Act cycles before changes are spread widely.
Quality projects track outcome, process and balancing measures; a balancing measure checks whether the change has caused harm elsewhere in the system.
On a run chart, six or more consecutive points above or below the median (a shift) or five or more points steadily rising or falling (a trend) signal nonrandom change.
The Pharmacists' Patient Care Process (JCPP 2014) has five steps: collect, assess, plan, implement, and follow up by monitoring and evaluating.
A hot debrief happens minutes after a resuscitation and is brief and team-focused; a cold debrief happens later, is structured and looks at system issues.
Last updated: October 2026
18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
Note
Exam scope: 2025 outline subtopics 3A4 (Quality Management and Process Improvement), 3B1 (Professional Practice Standards and Guidelines) and 3B4 (Interprofessional Healthcare Collaboration, e.g., policy development, debriefing). Error analysis tools such as RCA and FMEA are covered in Section 14.1, SBAR and I-PASS handoffs in Section 14.2, and research ethics and IRB review in Section 15.3.
- Quality Improvement Frameworks
- The Donabedian Model
Quality is measured through structure (resources and organization, such as pharmacist coverage hours), process (what is done, such as time from triage to antibiotic) and outcome (results for patients, such as sepsis mortality).
The IHI Model for Improvement
The Institute for Healthcare Improvement model asks three questions:
What are we trying to accomplish? Write a specific, measurable, time-bound aim. Example: "Increase the share of patients with septic shock who receive antibiotics within 60 minutes of triage from 55% to 80% by June."
How will we know that a change is an improvement? Choose measures.
What change can we make that will result in improvement? Choose change ideas.
Changes are tested with small Plan-Do-Study-Act (PDSA) cycles : one shift, one nurse or five patients at first, then larger tests, and then implementation and spread.
Types of Measures
- Measure Definition Example: ED sepsis antibiotic-timing project
- Outcome The result that matters to patients In-hospital sepsis mortality
- Process Whether the planned steps happen Minutes from triage to first antibiotic dose
Balancing Unintended effects elsewhere in the system Antibiotic use in patients who turn out not to have infection, C. difficile rates, delays for other ED patients
Lean and Six Sigma
Lean removes waste (waiting, motion, overprocessing, defects, excess inventory) using value-stream mapping and standard work. Example: redesign the path from order to administration of a time-critical antibiotic.
Six Sigma reduces variation using DMAIC : Define, Measure, Analyze, Improve, Control. Six Sigma performance equals 3.4 defects per million opportunities.
Displaying Data Over Time
Run charts plot data over time against the median. Signals of nonrandom change include:
- A shift : 6 or more consecutive points all above or all below the median
- A trend : 5 or more consecutive points all going up or all going down
- Too many or too few runs, or one point far outside the rest
Statistical process control charts add control limits, usually 3 standard deviations from the mean. They separate common-cause variation (built into the process; fixing it requires redesigning the process) from special-cause variation (a specific cause to find and address).
QI vs. Research
QI projects that improve local care usually do not need IRB review. Projects designed to produce generalizable knowledge, or that randomize patients or add risk, may be research and need review (Section 15.3). Ask the IRB when unsure, especially if the results will be published.
Medication Use Evaluation (MUE)
An MUE assesses how a drug is used against criteria approved in advance (indication, dose, monitoring, outcomes). It can be prospective (before dispensing), concurrent (during therapy) or retrospective . In the ED, MUEs commonly target thrombolytic dosing, 4F-PCC use, sugammadex, antimicrobial choices and high-cost antidotes. The findings drive order set changes, education and formulary decisions, and the measurement should be repeated after changes.
Professional Practice Standards and Guidelines
The Pharmacists' Patient Care Process (JCPP, 2014): Collect, Assess, Plan, Implement, and Follow-up: Monitor and Evaluate , with collaboration, communication and documentation throughout. It gives ED interventions a consistent structure.
ASHP Guidelines on Emergency Medicine Pharmacist Services (2021) describe the core responsibilities of the EM pharmacist:
- Bedside care, including resuscitation
- Prospective medication order review
- Medication histories and transitions of care
- Antimicrobial stewardship and culture follow-up
- Toxicology consultation
- Medication safety and emergency preparedness
- Education and scholarship
Credentialing and privileging: board certification (BCEMP), PGY2 emergency medicine residency and hospital privileges for collaborative practice agreements (for example, pharmacist-managed culture callbacks or medication protocols) define the pharmacist's scope locally, within state pharmacy law.
Developing Protocols and Policies
Identify the problem with data (MUE, error reports, delays).
Review the evidence and guidelines, and grade their strength (Section 15.3).
Write the protocol with all stakeholders: physicians, nursing, pharmacy, informatics and sometimes EMS.
Get approval through P&T, the relevant medical staff committees and nursing leadership.
Build it into the EHR (order sets, CDS) and smart pump libraries, and educate staff.
Measure, audit and revise.
Practice Advancement, Committees and Education
The 2024 outline tasks include advancing EM pharmacy practice, advocacy and committee work. Practical examples:
Documenting interventions and cost avoidance to justify pharmacist positions and extended coverage hours.
Serving on P&T, sepsis, stroke, trauma and resuscitation committees.
Precepting students and residents.
Teaching nurses and physicians.
Keeping the BCEMP credential through continuing education (Section 1.1).
- Interprofessional Collaboration
- Communication During Resuscitation
Closed-loop communication: the team leader gives a clear order to a named person, the receiver repeats it back, and the leader confirms. This is essential for weight-based or unfamiliar doses.
TeamSTEPPS (AHRQ) builds four teamwork skills: communication, team leadership, situation monitoring and mutual support . Its tools include briefs, huddles, debriefs, call-outs and check-backs.
CUS ("I am C oncerned, I am U ncomfortable, this is a S afety issue") and the two-challenge rule let any team member, including the pharmacist, stop a dangerous action. If a concern is raised twice and ignored, escalate up the chain of command.
The pharmacist's role in a code: prepare drugs and check doses, keep time for epinephrine and other repeat doses, anticipate the next drugs (antiarrhythmics, electrolytes, post-ROSC infusions), help with documentation, and act as the team's drug information source.
Debriefing
Debriefing after a resuscitation improves team performance and is supported by AHA resuscitation guidelines.
- Feature Hot debrief Cold debrief
- Timing Minutes after the event Hours to days later
- Length About 5 to 10 minutes 30 minutes or more
Participants The team that was present The team plus a facilitator, often with data such as defibrillator records
Focus Immediate safety issues, what went well, emotional check-in, equipment and drug restocking Systems issues, protocol gaps and education needs, using structured methods (for example PEARLS)
Psychological safety, a Just Culture approach to errors (Section 14.1) and second-victim support for staff after bad outcomes are essential. Debriefs often reveal medication system problems: missing drugs in kits, look-alike products and confusing concentrations. Feed these into the QI and formulary processes above.